Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $84.00

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) had its price target lowered by analysts at The Goldman Sachs Group from $94.00 to $84.00 in a report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective suggests a potential upside of 94.00% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Citigroup reissued a “focus list” rating and issued a $81.00 price target on shares of Apellis Pharmaceuticals in a report on Thursday, March 17th. Credit Suisse Group increased their target price on Apellis Pharmaceuticals to $49.00 in a research note on Friday. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $66.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Raymond James cut their target price on Apellis Pharmaceuticals from $114.00 to $102.00 in a research report on Thursday, May 5th. Finally, Robert W. Baird upped their target price on Apellis Pharmaceuticals from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Buy” and a consensus price target of $69.64.

Shares of Apellis Pharmaceuticals stock traded down $1.12 during trading on Tuesday, reaching $43.30. The stock had a trading volume of 7,931 shares, compared to its average volume of 1,107,854. The company has a market capitalization of $4.61 billion, a price-to-earnings ratio of -5.40 and a beta of 1.63. The company has a current ratio of 8.85, a quick ratio of 8.58 and a debt-to-equity ratio of 0.41. The stock has a fifty day moving average price of $48.20 and a two-hundred day moving average price of $44.97. Apellis Pharmaceuticals has a 52 week low of $27.50 and a 52 week high of $73.00.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative net margin of 866.81% and a negative return on equity of 607.37%. During the same quarter in the previous year, the firm earned ($2.32) EPS. On average, equities analysts forecast that Apellis Pharmaceuticals will post -5.58 EPS for the current fiscal year.

In other news, insider Lukas Scheibler sold 3,504 shares of the firm’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $56.96, for a total transaction of $199,587.84. Following the completion of the sale, the insider now directly owns 52,233 shares in the company, valued at $2,975,191.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $39.18, for a total value of $48,975.00. Following the transaction, the director now directly owns 263,774 shares of the company’s stock, valued at $10,334,665.32. The disclosure for this sale can be found here. Insiders have sold a total of 37,625 shares of company stock valued at $1,913,674 over the last three months. 9.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harbor Investment Advisory LLC lifted its holdings in Apellis Pharmaceuticals by 25.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,267 shares of the company’s stock valued at $60,000 after purchasing an additional 254 shares during the last quarter. Metropolitan Life Insurance Co NY grew its holdings in Apellis Pharmaceuticals by 1.7% during the third quarter. Metropolitan Life Insurance Co NY now owns 17,657 shares of the company’s stock worth $582,000 after purchasing an additional 291 shares during the period. MML Investors Services LLC grew its holdings in Apellis Pharmaceuticals by 4.6% in the 3rd quarter. MML Investors Services LLC now owns 7,970 shares of the company’s stock valued at $263,000 after buying an additional 354 shares in the last quarter. Virginia Retirement Systems ET AL lifted its position in shares of Apellis Pharmaceuticals by 7.1% during the 1st quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock worth $305,000 after buying an additional 400 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its holdings in Apellis Pharmaceuticals by 15.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,734 shares of the company’s stock valued at $202,000 after buying an additional 500 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Read More

Stock Target Advisor logo

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.